focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Regulatory News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 37.25
Bid: 37.00
Ask: 37.50
Change: -2.45 (-6.17%)
Spread: 0.50 (1.351%)
Open: 38.00
High: 38.50
Low: 36.75
Prev. Close: 39.70
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of WRAP Retail Offer

2 Apr 2024 16:51

RNS Number : 0355J
Sareum Holdings PLC
02 April 2024
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.

THE COMMUNICATION OF THIS ANNOUNCEMENT AND ANY OTHER DOCUMENTS OR MATERIALS RELATING TO THE WRAP RETAIL OFFER AS A FINANCIAL PROMOTION IS ONLY BEING MADE TO, AND MAY ONLY BE ACTED UPON BY, THOSE PERSONS IN THE UNITED KINGDOM FALLING WITHIN ARTICLE 43 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (WHICH INCLUDES AN EXISTING MEMBER OF THE SAREUM HOLDINGS PLC). ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IS AVAILABLE ONLY TO SUCH PERSONS AND WILL BE ENGAGED IN ONLY WITH SUCH PERSONS. THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY, AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL OR ISSUE, OR ANY SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR, ANY SECURITIES OF THE SAREUM HOLDINGS PLC.

 

2 April 2024

Sareum Holdings plc

("Sareum" or the "Company")

 

Result of WRAP Retail Offer

 

Sareum Holdings plc is pleased to announce the outcome of the offer made by the Company to retail investors via the Winterflood Retail Access Platform ("WRAP"), which has now closed (the "WRAP Retail Offer").

 

The Company is pleased to confirm that it has raised gross proceeds of approximately £1.12m at a price of 10 pence per new Ordinary Share via the WRAP Retail Offer, and accordingly will issue 11,189,733 new Ordinary Shares ("WRAP Retail Shares").

 

The net proceeds of the WRAP Retail Offer, together with the conditional Placing and Subscription of up to £1.2m announced on 28 March 2024, will be used for further advancement of the Company's clinical and pre-clinical projects, potentially including further pre-clinical studies on SDC-1802.

 

Of the £1.12m raised from the WRAP Retail Offer, £10,000 is from a director of the Company (as previously committed in the announcement on 28 March) and £50,000 is additional interest from an institutional investor on the placing book, which WRAP has agreed to settle.

Completion of the WRAP Retail Offer is conditional, inter alia, upon the completion of the Placing and admission of the WRAP Retail Shares to trading on AIM ("Admission"). It is anticipated that Admission will become effective and that dealings in the WRAP Retail Shares will commence on AIM, at 8:00 a.m. on 5 April 2024.

 

Capitalised terms used in this announcement shall, unless defined in this announcement or unless the context provides otherwise, bear the same meaning ascribed to such terms in the announcements made by the Company at 07:00 a.m. on 28 March 2024.

 

 

 For Further Information:

 

Sareum Holdings plc

Tim Mitchell, CEO

Lauren Williams, Head of Investor Relations

 

01223 497700

ir@sareum.co.uk

Strand Hanson Limited (Nominated Adviser)

James Dance / James Bellman

 

020 7409 3494

Hybridan LLP (Joint Corporate Broker and Sole Broker to the Placing)

Claire Noyce

 

020 3764 2341

Consilium Strategic Communications (Financial PR)

Jessica Hodgson / Davide Salvi / Kumail Waljee

0203 709 5700

 

Further information on the Company can be found on its website at https://sareum.com/.

 

The Company's LEI is 213800PKERN2DY8FFM72.

 

This announcement should be read in its entirety. In particular, the information in the "Important Notices" section of the announcement should be read and understood.

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended by virtue of the Market Abuse (Amendment) (EU Exit) Regulations 2019 ("UK MAR").

 

 

Important Notices

 

The content of this announcement has been prepared by and is the sole responsibility of the Company

This announcement and the information contained herein is not for release, publication or distribution, directly or indirectly, in whole or in part, in or into or from the United States (including its territories and possessions, any state of the United States and the District of Columbia (the "United States" or "US")), Australia, Canada, New Zealand, Japan, the Republic of South Africa, any member state of the EEA or any other jurisdiction where to do so might constitute a violation of the relevant laws or regulations of such jurisdiction.

 

The WRAP Retail Offer Shares have not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act") or under the applicable state securities laws of the United States and may not be offered or sold directly or indirectly in or into the United States. No public offering of the WRAP Retail Offer Shares is being made in the United States. The WRAP Retail Offer Shares are being offered and sold outside the United States in "offshore transactions", as defined in, and in compliance with, Regulation S under the US Securities Act ("Regulation S") to non-US persons (within the meaning of Regulation S). In addition, the Company has not been, and will not be, registered under the US Investment Company Act of 1940, as amended.

 

This announcement does not constitute an offer to sell or issue or a solicitation of an offer to buy or subscribe for WRAP Retail Offer Shares in the United States, Australia, Canada, New Zealand, Japan, the Republic of South Africa, any member state of the EEA or any other jurisdiction in which such offer or solicitation is or may be unlawful. No public offer of the securities referred to herein is being made in any such jurisdiction.

 

This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America. This announcement is not an offer of securities for sale into the United States. The securities referred to herein have not been and will not be registered under the US Securities Act, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of securities is being made in the United States.

 

The distribution of this announcement may be restricted by law in certain jurisdictions and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

 

WRAP is a proprietary technology platform owned and operated by Winterflood Securities Ltd (registered address at Riverbank House, 2 Swan Lane, London EC4R 3GA; FRN 141455). Winterflood Securities Ltd ("Winterflood") is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting exclusively for the Company and for no-one else and will not regard any other person (whether or not a recipient of this announcement) as its client in relation to the WRAP Retail Offer and will not be responsible to anyone other than the Company for providing the protections afforded to its clients, nor for providing advice in connection with the WRAP Retail Offer, Admission and the other arrangements referred to in this announcement.

 

The value of Ordinary Shares and the income from them is not guaranteed and can fall as well as rise due to stock market movements. When you sell your investment, you may get back less than you originally invested. Figures refer to past performance and past performance is not a reliable indicator of future results. Returns may increase or decrease as a result of currency fluctuations.

 

Certain statements in this announcement are forward-looking statements which are based on the Company's expectations, intentions and projections regarding its future performance, anticipated events or trends and other matters that are not historical facts. These forward-looking statements, which may use words such as "aim", "anticipate", "believe", "intend", "estimate", "expect" and words of similar meaning, include all matters that are not historical facts. These forward-looking statements involve risks, assumptions and uncertainties that could cause the actual results of operations, financial condition, liquidity and dividend policy and the development of the industries in which the Company's businesses operate to differ materially from the impression created by the forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Given those risks and uncertainties, prospective investors are cautioned not to place undue reliance on forward-looking statements.

 

These forward-looking statements speak only as at the date of this announcement and cannot be relied upon as a guide to future performance. The Company and Winterflood expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein to reflect actual results or any change in the assumptions, conditions or circumstances on which any such statements are based unless required to do so by the Financial Conduct Authority, the London Stock Exchange or applicable law.

 

The information in this announcement is for background purposes only and does not purport to be full or complete. None of Winterflood or any of its affiliates, accepts any responsibility or liability whatsoever for, or makes any representation or warranty, express or implied, as to this announcement, including the truth, accuracy or completeness of the information in this announcement (or whether any information has been omitted from the announcement) or any other information relating to the Company or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of the announcement or its contents or otherwise arising in connection therewith. Winterflood and its affiliates, accordingly disclaim all and any liability whether arising in tort, contract or otherwise which they might otherwise be found to have in respect of this announcement or its contents or otherwise arising in connection therewith.

 

Any indication in this announcement of the price at which the Ordinary Share have been bought or sold in the past cannot be relied upon as a guide to future performance. Persons needing advice should consult an independent financial adviser. No statement in this announcement is intended to be a profit forecast and no statement in this announcement should be interpreted to mean that earnings or target dividend per share of the Company for the current or future financial years would necessarily match or exceed the historical published earnings or dividends per share of the Company.

 

Neither the content of the Company's website (or any other website) nor the content of any website accessible from hyperlinks on the Company's website (or any other website) is incorporated into or forms part of this announcement. The WRAP Retail Offer Shares to be issued or sold pursuant to the WRAP Retail Offer will not be admitted to trading on any stock exchange other than the London Stock Exchange.

 

It is further noted that the WRAP Retail Offer is only open to investors in the United Kingdom who fall within Article 43 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (which includes an existing member of the Company).

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROIBUGDSLSGDGSD
Date   Source Headline
5th Jun 201712:13 pmRNSChk1 Clinical Trials Update
31st May 20177:00 amRNSSierra Oncology Granted US and EU Patents
25th May 20177:00 amRNSSierra Oncology to Present at ASCO Annual Meeting
9th May 20177:00 amRNSSareum to Present at BioTrinity 2017
9th Mar 20177:00 amRNSDirector Shareholding
20th Feb 20177:00 amRNSHalf-year Results
9th Feb 20177:00 amRNSNotice of Interim Results
9th Jan 201712:05 pmRNSMilestone Payment from Chk1 Licence Agreement
22nd Dec 20169:47 amRNSResult of General Meeting
15th Dec 201611:38 amRNSResult of AGM
6th Dec 20167:00 amRNSDirectors' Remuneration & General Meeting
29th Nov 20167:00 amRNSSareum to Present at AACR-NCI-EORTC Conference
21st Nov 20167:00 amRNSNotice of AGM
2nd Nov 20167:00 amRNSFinal Results
24th Oct 20167:00 amRNSSuccessful Outcome from TYK2 Feasibility Study
17th Oct 20167:00 amRNSJapan and Singapore Patent Grants
27th Sep 201612:02 pmRNSLicence agreement for Chk1 Inhibitor CCT245737
3rd Aug 20167:00 amRNSChina & HK Patent Grants for Sareum's Aurora+FLT3
28th Jul 20167:00 amRNSMovement in share price
23rd May 201612:00 pmRNSClinical Trials CHK1 Inhibitor CCT245737 to Open
17th May 20167:00 amRNSChange of Director
5th Apr 201610:38 amRNSCHK1 Approved for Clinical Trials
24th Mar 201611:54 amRNSPlacing
14th Mar 20167:00 amRNSIssue of Options
10th Mar 201612:55 pmRNSShare price movement
24th Feb 20167:01 amRNSResearch & Co-Development Collaborations Update
24th Feb 20167:00 amRNSHalf-Yearly Results for December 2015
1st Feb 20167:00 amRNSCHK1 Clinical Trial Application Submissions
15th Dec 201511:20 amRNSResult of AGM
15th Dec 20157:00 amRNSCHK1 Clinical Trial Applications
13th Nov 201510:15 amRNSNotice of AGM
26th Oct 20157:00 amRNSFinal Results
15th Sep 20157:00 amRNSUS and European Patent Grants for Aurora+FLT3
23rd Jul 20157:00 amRNSCHK1 Research Update
17th Jun 20157:00 amRNSFunding Award from Innovate UK
28th May 20157:00 amRNSPlacing
21st May 20157:00 amRNSSareum Launches New Website
12th May 20157:01 amRNSSareum to Present at BioTrinity 2015
7th May 20157:00 amRNSEarly Conclusion of Equity Swap Agreement
16th Mar 20157:00 amRNSChange of Adviser
20th Jan 20157:00 amRNSFurther US Patent Grant for Kinase Inhibitors
13th Oct 20148:20 amRNSHolding(s) in Company
1st Oct 20147:00 amRNSPromising Step in Psoriasis Drug Development
22nd Sep 20147:00 amRNSCHK1 Patent Update
2nd Jul 20147:00 amRNSJapanese Patent Grant for Kinase Inhibitors
30th Jun 20142:15 pmRNSTotal Voting Rights
26th Jun 20147:00 amRNSPreclinical Proof of Concept in TYK2 Programme
22nd Jan 20147:00 amRNSCHK1 Patent Update
25th Oct 20137:00 amRNSSareum to Present at London Investor Show
10th Sep 20127:00 amRNSFinancing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.